Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of July 2021, specifically dated July 27, 2021. The filing discloses a strategic transaction involving the acquisition of an asset portfolio targeting alpha-synuclein therapeutics, including the Parkinson's disease vaccine candidate PD01, from Affiris AG.
Key Financial Metrics and Transaction Details
- Acquisition Value: Total consideration of USD 58.7 million for the Transferred Assets and USD 5 million in cash.
- Equity Issuance: 7,106,840 shares issued at a price of USD 8.26 per share.
- Premium: The transaction price represents a 10.7% premium to the closing share price on July 23, 2021.
- Debt Financing: Two Convertible Note Agreements with an aggregate principal amount of USD 25 million (USD 12.5 million each).
- Net Proceeds: USD 25 million from the Convertible Notes.
- Conversion Terms: Notes are convertible at USD 8.26 per share; no interest is borne.
- Repayment Date: July 26, 2022, if not converted.
Material Changes and Outlook
The primary material change is the expansion of the company's therapeutic pipeline through the acquisition of Affiris AG's alpha-synuclein program. The transaction is subject to customary regulatory approval in Austria and is expected to close in the beginning of Q4 2021. The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period, as this is a current event report rather than a periodic financial statement.
Risks and Contingencies
- Regulatory Approval: The acquisition is contingent upon regulatory approval in Austria.
- Dilution: The issuance of approximately 7.1 million shares and the potential conversion of USD 25 million in notes will increase the share count.
- Liquidity: While USD 25 million in net proceeds are secured via notes, the company must manage the repayment obligation if conversion does not occur by July 2022.
Investor Verification Checklist
- Verify the status of Austrian regulatory approvals required for the asset transfer.
- Confirm the exact closing date in Q4 2021 to assess the timing of asset integration.
- Monitor the conversion status of the USD 25 million Convertible Notes prior to the July 26, 2022 repayment date.
- Review the full text of Exhibit 99.1 (Press Release) for additional terms regarding the Asset Purchase Agreement.